5 курс / Психиатрия и наркология для детей и взрослых (доп.) / Psikhiatria_Psikhiatria_i_psikhofarmakoterapia_im_P_B_Gannushkina (1)

Список исп. литературыСкрыть список

1. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999; 9: 99–107. 2. Padla D. Quetiapine resolves psychotic depression in an adolescent boy. J Child Adolesc Psychopharmacol 2001; 11: 207–8. 3. Parraga HC, Parraga MI, Woodward RL, Fenning PA. Quetiapine treatment of children with Tourette's syndrome: report of two cases. J Child Adolesc Psychopharmacol 2001; 11: 187–91. 4. Brecher M, Rak IW, Westhead EK et al. The long0term effect of quetiapine (‘Seroquel’) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000; 4: 287–92. 5. Srisuraponont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia. Cochrane Database Syst Rev 2000; 2. 6. Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel trial 13 Study group. Biol Psychiatry 1997; 42: 233–46. 7. Copolov DL, Link CG, Kowalcyk B. A multicentre, duble-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000; 30: 95–1I 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000; 30: 95–105. 8. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51–68. 9. Emsley RA, Raniwalla J, Bailey PJ, Jones AM. A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 2000; 15: 121–31. 10. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psych Neurosci 2001; 26: 137–49. 11. Zarate CA, Rothschild A, Fletcher KE et al. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry 2000; 63,3: 185–9. 12. De Nayer A, Windhager E, Irmansyan, Larmo I et al. Efficacy and tolerability of quetiapine in patients with schizophrenia-switched from other antipsychotics. Int J psych Clin Pract 2003; 7: 59–66. 13. Mullen J, Jibson MD, Sweitzer D. A cjmparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Therap 2001; 23 (11): 1839–54. 14. Tariot PN, Salzman C, Yeung PP et al. Clinical improvement and tolerability is Maintaned long-term in elderly patients with psychotic disorders treated with quetiapine. Am Psych Association, Ann Meeting 1999; 219: Abs NR542. 15. Potenza MN, McDougle CJ. Potential of atypical antipsychotics in the treatment of non-psychotic disorders. CNS Drugs 1998; 9: 213–32.